Related Experiment Videos
Clinical courses and changes of pancreatic beta-cell function in young-onset diabetics: report of two cases
1Department of Internal Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C.
Insights
Distinguishing between types of diabetes in young patients is crucial for treatment. This study highlights two cases, one progressing to insulin dependence (Type 1) and another managed with oral agents (Type 2), emphasizing distinct clinical courses.
Area of Science:
- Endocrinology
- Immunology
Background:
- Accurate diabetes classification in young individuals is challenging but vital for effective treatment strategies.
- Distinguishing between insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in youth is often complex.
Observation:
- Two young-onset diabetic patients initially treated with insulin were later switched to oral hypoglycemic agents (OHA) due to comparable beta-cell function to NIDDM patients.
- Case 1 showed progressive deterioration in glycemic control and beta-cell function, ultimately requiring insulin therapy.
- Case 2 maintained preserved beta-cell function with OHA, achieving near-normoglycemia through improved diet and compliance.
Findings:
- Case 1 was identified as a slowly progressive Type 1 diabetes patient.
- Case 2 was classified as a young Type 2 diabetes patient.
- Human leukocyte antigen (HLA)-DR3 was present in Case 1 but absent in Case 2, supporting the distinct classifications.
Implications:
- These cases underscore the importance of individualized assessment and monitoring for precise diabetes diagnosis in young patients.
- Understanding the differing trajectories of young-onset diabetes is critical for optimizing long-term management and patient outcomes.
- Genetic markers like HLA-DR3 may aid in differentiating diabetes subtypes in challenging pediatric cases.
Abstract:
Accurate classification of diabetes in some young patients is difficult but clearly of importance in deciding the appropriate treatment. We report the different clinical courses and beta-cell function changes in 2 young-onset diabetics. In the beginning, each of them was considered to be a patient with insulin-dependent diabetes mellitus (IDDM) and was treated with insulin. Then, treatment was shifted from insulin to oral hypoglycemic agents (OHA) because each patient's beta-cell function was comparable to that of patients with non-insulin-dependent diabetes mellitus (NIDDM). In case 1, the patient's glycemic control and beta-cell function progressively deteriorated and finally insulin therapy was required. In case 2, the patient was continuously treated with OHA. Although his blood glucose was not well-controlled, his beta-cell function had been well-preserved. Recently he achieved near-normoglycemia by improving his diet and OHA compliance. Clearly, case 1 was a slowly progressive Type 1 DM patient and case 2 was a young Type 2 DM patient. This classification was further supported by the finding that the patient in case 1 had human leukocyte antigen (HLA)-DR3, but the patient in case 2 did not.